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Abstract. Tau abnormal hyperphosphorylation and the formation of neurofibrillary tangles in the Alzheimer’s disease (AD)
brain is the result of upregulation of tau kinases. In a group of 729 Spanish late-onset AD patients and 670 healthy controls, we
examined variations into a set of 20 candidate genes of kinases involved in tau phosphorylation at AD-related sites (PRKACB;
CAMK2A; MARK1, 2, 3 and 4; CSNK1D; CDC2; RPS6KB1 and 2; p38 and ; IB1; JNK1, 2 and 3; MEK1 and 2; ERK1
and 2), to address hypotheses of genetic variation that might influence both AD risk and age at disease onset. There was an
increased frequency of RPS6KB2 (intron 2, rs917570) minor allele in patients (50%) versus controls (39%) (OR = 1.52; 95%
CI 1.30–1.77; p = 1.24 × 10−5 Bonferroni corrected), and the presence of this minor allele was significantly (p = 4.2 × 10−5)
associated with a 3-years later onset of AD (mean age 74.1 years) when compared to age at onset of non-minor allele carriers
(mean age 71.1 years). In APOE non-4 allele carriers, the combined effect of AD-associated risk alleles from the genes of
CDC2, RPS6KB1 and 2, p38, JNK (1, 2 and 3), MEK2, and ERK2 was significantly (p = 0.002) associated with a late-onset
(>76 years) of AD. The CDC2 AGC haplotype derived from SNPs in introns 3 (rs2448347), 5 (rs2456772), and 7 (rs1871447)
showed a protective effect against AD in APOE non-4 allele carriers (permutation p = 1.0 × 10−4) with a frequency of 9% in
cases and 15% in controls. Common genetic variation in the tau kinases pathway does underlie individual differences not only
in susceptibility to AD but also in disease phenotype (age at disease onset).
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INTRODUCTION
One of the neuropathological hallmarks in
Alzheimer’s disease (AD) is neurofibrillary tangles
(NFTs), which are composed of the microtubule-
binding protein tau that is hyperphosphorylated [1–3].
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Tau abnormal hyperphosphorylation is the result
of upregulation of tau kinases, and GSK3- and
CDK5 are among the kinases most implicated in the
abnormal hyperphosphorylation of tau in AD brains
[3]. The inhibition of abnormal hyperphosphorylation
of tau is one of the most promising therapeutic
targets for the development of disease modifying
drugs, and it has been suggested that inhibition of
either both GSK3- and CDK5 or one of these two
kinases plus PRKA or CAMK2 might be required to
inhibit AD neurofibrillary degeneration [4]. All this
data postulates a role for tau kinases as interesting
genetic targets for association analysis of AD. We
have previously examined the contribution of some
tau kinases genes such as GSK3- [5], CDK5 [6],
CDK5R1 [7], DYRK1A [8], and TTBK1 [9] to the
susceptibility to AD. In the present study, we extended
previous investigations by evaluating variations into
an exhaustive list of all known genes of kinases
involved in tau phosphorylation at AD-related sites,
in relation to both AD risk and age at disease onset, in
a Spanish cohort.
METHODS
Subjects
The study included 729 AD patients (67% women;
mean age at study 77.2 years; SD 8.0; range 61–103
years; mean age at onset 73.3 years; SD 7.8; range
60–100 years) who met NINCDS/ADRDA criteria for
probable AD [10]. All AD cases were defined as spo-
radic because their family history did not mention
any first-degree relative with dementia. AD patients
were recruited from the Departments of Neurology
of University Hospital “Marque´s de Valdecilla” (San-
tander, Spain) and Hospital “La Paz” (Madrid, Spain),
and from Alzheimer Center Reina Sofia Foundation
(Madrid, Spain). The large majority of patients was
living in the community and had been referred by their
general practitioner; few had been admitted from hos-
pital wards or nursing home facilities. Control subjects
were 670 unrelated individuals (64% women; mean
age 78.3 years; SD 9.4; range 60–104 years) ran-
domly selected from nursing homes. These subjects
had complete neurologic and medical examinations
that showed that they were free of significant illness
and had Mini Mental State Examination scores of 28
or more, which were verified by at least one subse-
quent annual following-up assessment. The controls
arose from the same base population as the cases.
The AD and control samples were Caucasians orig-
inating from a limited geographical area in northern
Spain (Santander) and from the central area of Spain
(Madrid).
Genotyping
Blood samples were taken after written informed
consent had been obtained from the subjects or
their representatives. The study was approved by
the ethical committees of the University Hospital
“Marque´s de Valdecilla”, Alzheimer Center Reina
Sofia Foundation, and the Hospital “La Paz”. Geno-
typing of cAMP-dependent kinase A catalytic subunit
 (PRKACB), calmodulin-dependent protein kinase-II
 (CAMK2A), microtubule-affinity regulating kinases
(MARK1, 2, 3 and 4), casein kinase-1 δ (CSNK1D),
cell division cycle 2 kinase (CDC2), ribosomal S6
protein kinases (RPS6KB1 and 2), p38 and , islet-
brain 1/C-Jun N-terminal kinase interacting protein
1 (IB1), C-Jun N-terminal kinases (JNK1, 2 and
3), MEK1 and 2, and extracellular signal-regulated
kinases (ERK1 and 2) was performed using the iPLEX
Gold assay on the MassArray system (Sequenom Inc.,
San Diego, USA). We used data from the HapMap
project (http://www.hapmap.org) to select htSNPs cap-
turing 92% of PRKACB genetic variability, 91% of
CAMK2A, 91% of MARK1, 90% of MARK2, 89% of
MARK3, 91% of MARK4, 100% of CSNK1D, 90% of
CDC2, 93% of RPS6KB1, 100% of RPS6KB2, 91% of
p38, 100% of p38, 100% of IB1, 92% of JNK1, 88%
of JNK2, 87% of JNK3, 80% of MEK1, 90% of MEK2,
100% of ERK1, and 93% of ERK2 genetic variability
in Caucasians. SNPs were chosen among those with
minor allele frequencies ≥5% using Haploview v3.2
software (http://www.broad.mit.edu/mpg/haploview)
with an r2 threshold of 0.8.
Statistical analysis
Hardy-Weinberg equilibrium (HWE) was calcu-
lated for the htSNPs in the control population using
Pearson’s χ2 statistics. We assessed pairwise linkage
disequilibrium (LD) between the htSNPs by D’ and
r2 statistics. Haplotype reconstruction and their fre-
quencies in cases and controls were estimated by an
expectation-maximization algorithm, method imple-
mented in Haploview 3.32. Pearson’s χ2 statistics
were performed to compare allele and haplotype dis-
tribution of the patients and control for each htSNP.
Allelic distributions were assessed by logistic regres-
sion using the package SPSS 13.0 for Windows (SPSS,
Inc, Chicago, Illinois). In order to obtain a measure
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of significance corrected for multiple testing, we used
Bonferroni’s method to correct our nominal p-values
for all 85 tests performed, corresponding to the 85
SNPs analyzed. In our haplotype analysis we chose a
less conservative approach, permutation test, to adjust
for multiple testing. By using Student’s t test and
stratifying by APOE 4 allele status, we tested for dif-
ferences in age at disease onset depending on allele
distributions of the AD-associated risk SNPs. In addi-
tion, we calculated for each subject a cumulative
genetic risk score (GRS) defined as the number of nom-
inally significant (p < 0.05) AD-associated risk alleles
from our list of tau kinases pathway genes, and we
correlated the GRS with age at AD onset using Pear-
son’s r2; moreover, we compared by ANOVA test the
GRS distributions across patient’s age at disease onset
divided into quintiles.
RESULTS
PRKACB rs7515976 and rs11163911, CAMK2A
rs6881743, MARK2 rs11231637, MARK4 rs344807,
CSNK1D rs12601586, CDC2 rs3213058, RPS6KB1
rs180523, p38 rs742186, JNK2 rs6868333, MEK2
rs350896 and ERK1 rs11865086 SNPs were signifi-
cantly deviated from HWE, and therefore, they were
excluded from the analysis; these deviations could
be the result of a genotyping error. As shown in
Table 1, the distribution of the minor allele frequen-
cies of the tau kinases genes did not differ significantly
between AD and control groups, except for RPS6KB2
(intron 2, rs917570) minor allele that was increased
in patients (50%) versus controls (39%) (OR = 1.52;
95% CI 1.30–1.77; p = 1.24 × 10−5 Bonferroni cor-
rected). Haplotype distributions were not significantly
different between cases and controls in the overall anal-
ysis or after stratification by APOE 4 allele, except
for CDC2 gene (Table 2): the AGC haplotype derived
from SNPs in introns 3 (rs2448347), 5 (rs2456772),
and 7 (rs1871447) showed a protective effect against
AD only in APOE 4 allele noncarriers (permutation
p = 1.0 × 10−4), with a frequency of 9% in cases and
15% in controls.
Age of AD onset was 3 years later (mean age
74.13, SD 7.51) in patients carrying RPS6KB2
(intron 2, rs917570) minor allele compared to
non-minor allele carriers (mean age 71.16, SD
8.22; p = 4.2 × 10−5), with this significant associ-
ation being equally present in APOE 4 allele
carriers (p = 0.006) and APOE non-4 allele carriers
(p = 0.002). We selected 9 htSNPs (CDC2 rs1871447,
RPS6KB1 rs8071475, RPS6KB2 rs917570, p38
rs851019, JNK1 rs10857565, JNK2 rs6601105, JNK3
rs4693136, MEK2 rs10250, and ERK2 rs1063311)
with nominally significant (p < 0.05) AD association
from the tau kinases pathway (Table 1), and examined
the simultaneous effect of all these AD-associated risk
alleles (genetic risk score, GRS) on the age of AD
onset. In APOE non-4 allele carriers, we found a sta-
tistically significant correlation (r2 = 0.177; p = 0.001)
between GRS and age at AD onset, and this correla-
tion remained statistically significant after removing
RPS6KB2 (intron 2, rs917570) from the analysis
(r2 = 0.118, p = 0.026); conversely, in APOE 4 allele
carriers there was no correlation (r2 = 0.75; p = 0.15)
between GRS and age at onset. When age at AD
onset was divided into quintiles (Fig. 1), GRS values
increased significantly (p = 0.002) in late-onset (>76
years) patients, in the APOE non-4 allele carriers; in
contrast, there were no statistically significant GRS
differences (p = 0.49) between quintile groups in
APOE 4 allele carriers.
DISCUSSION
The largest genome-wide association study (GWA)
in AD [11] did not find significant results for genes
directly related to tau phosphorylation. However, it
cannot be discarded that these genes in the tau kinases
pathway are among the genes with significant nom-
inal association but without reaching significance
(p < 5 × 10−8) after adjustment for multiple testing
in GWAs; in addition, it is also possible that some
of the SNPs analyzed in our study were not present
in the arrays used in GWAs or were lost during the
strict quality control checks. Moreover, genes harbor-
ing markers with only modest evidence of association
can be identified if they belong to the same biologi-
cal pathway or mechanism; therefore, pathway-based
approaches, which jointly consider multiple variants
in interacting or related genes, might complement the
most-significant SNPs/genes approach for interpret-
ing GWA data on complex diseases [12, 13]. In fact,
genetic variation in the immune system and in lipid
metabolism pathways is a cause of AD susceptibil-
ity [14, 15]. Tau kinases genes can be divided into
two major groups, i.e., the proline-directed tau kinases
and non-proline-directed tau kinases (Fig. 2). The non-
proline-directed tau kinases genes CAMK2A, MARKs
(1, 2, 3 and 4), and PRKACB, were not associated
with the AD risk in our study. Tau-tubuline kinase 1
(TTBK1) is another non-proline-directed kinase and
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Table 1
Minor allele frequencies distribution of tau kinases genes in AD patients and controls
Gene SNP MAF, AD/C p-value Gene SNP MAF, AD/C p-value
PRKACB rs6695305 0.45/0.46 0.494 p38 rs2076139 0.18/0.19 0.825
rs6576960 0.45/0.46 0.443 IB1 rs1554338 0.06/0.06 0.838
rs2250806 0.23/0.23 0.773 rs7114162 0.30/0.30 0.838
rs12118723 0.44/0.45 0.641 JNK1 rs10857561 0.32/0.33 0.312
rs6695851 0.44/0.44 0.917 rs10857565 0.21/0.24 0.033
CAMK2A rs10515639 0.24/0.25 0.434 rs7086275 0.44/0.45 0.677
rs13354653 0.20/0.21 0.616 JNK2 rs12519649 0.12/0.14 0.202
rs13357922 0.36/0.37 0.529 rs17629029 0.25/0.24 0.506
rs4958445 0.27/0.28 0.496 rs6601105 0.37/0.41 0.009
rs4958452 0.46/0.46 0.900 rs3111515 0.40/0.41 0.787
rs3756577 0.14/0.14 0.992 rs13185784 0.28/0.28 0.743
rs930212 0.40/0.40 0.911 rs4147385 0.26/0.25 0.439
rs3776825 0.31/0.31 0.833 rs4639174 0.18/0.16 0.271
rs3797617 0.18/0.17 0.756 rs11955223 0.46/0.48 0.432
rs6869634 0.18/0.18 0.616 rs6895740 0.35/0.35 0.992
rs10051644 0.26/0.27 0.421 JNK3 rs4488910 0.14/0.15 0.221
rs17656349 0.40/0.42 0.418 rs12508801 0.16/0.17 0.612
MARK1 rs1933002 0.23/0.23 0.916 rs7688651 0.38/0.38 0.973
rs2378400 0.31/0.30 0.455 rs7677400 0.16/0.16 0.843
rs12123306 0.45/0.43 0.363 rs6826702 0.22/0.23 0.314
MARK2 rs4980530 0.35/0.37 0.328 rs9307016 0.18/0.20 0.316
MARK3 rs1989565 0.35/0.34 0.514 rs1460757 0.37/0.38 0.348
rs12896612 0.36/0.35 0.615 rs6531905 0.25/0.25 0.783
rs9671414 0.30/0.32 0.239 rs4403040 0.37/0.38 0.555
MARK4 rs12981145 0.51/0.49 0.238 rs6821745 0.17/0.20 0.058
rs12984234 0.26/0.24 0.235 rs4693136 0.16/0.12 0.003
rs11667235 0.31/0.28 0.118 rs12505566 0.18/0.20 0.052
CSNK1D rs7209167 0.42/0.43 0.750 rs3775170 0.30/0.29 0.570
rs4789846 0.12/0.12 0.935 rs2589518 0.16/0.13 0.075
rs11653735 0.18/0.20 0.375 MEK1 rs8042644 0.11/0.09 0.243
CDC2∗ rs2448347 0.41/0.44 0.078 rs7181936 0.31/0.32 0.938
rs2456772 0.26/0.25 0.775 rs8039880 0.20/0.19 0.609
rs1871447 0.27/0.24 0.033 MEK2 rs350887 0.25/0.23 0.423
RPS6KB1 rs8071475 0.31/0.28 0.023 rs350895 0.31/0.29 0.415
rs1292034 0.47/0.44 0.173 rs350903 0.44/0.47 0.108
rs180531 0.24/0.24 0.668 rs10250 0.45/0.49 0.033
rs180515 0.32/0.33 0.926 rs350911 0.32/0.33 0.670
rs1051424 0.14/0.15 0.221 rs350916 0.45/0.47 0.415
RPS6KB2 rs917570 0.50/0.39 1.24 ×10−5 ERK1 rs7698 0.13/0.12 0.726
p38 rs851019 0.42/0.45 0.041 ERK2 rs9610470 0.29/0.27 0.377
rs1100857 0.10/0.10 0.477 rs1063311 0.51/0.47 0.023
rs16884919 0.09/0.09 0.989 rs13515 0.22/0.20 0.289
rs3804452 0.14/0.16 0.102
p-values not corrected for multiple comparisons; in bold, significative p-values after multiple testing correction; ∗CDC2 AGC haplotype
(rs2448347 G/A, rs2456772 G/C and rs1871447 C/T) was protective against AD.
Table 2
Haplotype association analysis between CDC2 gene and AD stratified by APOE 4 allele
APOE 4 allele noncarriers APOE 4 allele carriers Total sample
Haplotype AD, control p-value Permutation AD, control p-value Permutation AD, control p-value Permutation
frequency p-value∗ frequency p-value∗ frequency p-value∗
GGC 0.34, 0.31 0.15 0.57 0.34, 0.33 0.75 1.00 0.36, 0.33 0.16 0.53
AGT 0.27, 0.22 0.02 0.08 0.26, 0.23 0.42 0.97 0.26, 0.23 0.02 0.08
GCC 0.23, 0.20 0.26 0.81 0.20, 0.18 0.49 0.99 0.22, 0.21 0.49 0.93
AGC 0.09, 0.15 1.0 × 10−4 1.0 × 10−4 0.11, 0.16 0.06 0.27 0.11, 0.18 3.3 × 10−7 3.0 × 10−5
Haplotype block consists of SNPs rs2448347 (intron 3), rs2456772 (intron 5), and rs1871447 (intron 7). Rare haplotypes (total frequency < 0.05)
were excluded from the analysis. ∗Multiple testing correction with 10,000 permutations.
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Fig. 1. Box plot showing correlation between age at AD onset
divided into quintiles on the x-axis and cumulative genetic risk score
(GRS) on the y-axis, in APOE non-4 allele carriers. GRS is defined
as the number of nominally significant (p < 0.05) AD-associated risk
alleles from our list of tau kinases pathway genes (CDC2 rs1871447,
RPS6KB1 rs8071475, RPS6KB2 rs917570, p38 rs851019, JNK1
rs10857565, JNK2 rs6601105, JNK3 rs4693136, MEK2 rs10250,
and ERK2 rs1063311).
we recently [9] found that subjects carrying two copies
of the minor allele of markers in introns 1, 5 and 9
had a reduced risk of AD; these findings have been
replicated in Han Chinese [16]. The proline-directed
tau kinases genes CSNK1D and the mitogen-activated
protein kinase (MAPK) family comprising p38s ( and
), JNKs (1, 2 and 3) and its activator IB1, and ERKs
(1 and 2) and their activators MEKs (1 and 2), were not
associated with AD risk in the present study. However,
the interaction between the minor allele of a polymor-
phism in the 5´ regulatory region (−499, rs1554338)
of IB1 and either the major allele of LRP1 (exon 3,
rs1799986) [17] or the minor allele of LRP8 (exon 19,
rs5174) [18] has been associated with AD risk.
We have shown in this study, for the first time, that
the RPS6KB2 (intron 2, rs917570) minor allele was
associated with increased AD risk and a later onset of
AD, and that the combined effect of AD-associated
risk alleles from the genes of CDC2, RPS6KB1 and 2,
p38, JNK (1, 2 and 3), MEK2 and ERK2, was also
associated with a later onset of AD, in APOE non-
4 allele carriers. Late-onset AD patients might have
a different genetic background compared with early-
onset AD patients that might enhance the effect of all
these tau kinases pathway risk alleles, leading to a late
expression of the disease. A polymorphism in the exon
6 (rs321239) of CDC2 was associated with AD risk in
the Swedish population [19], and a haplotype derived
from SNPs in exon 6 (rs321239) and exon 7 (rs2456777
and rs2456778) increased the risk of AD in APOE 4
carriers from Sicily [20], but a large study in Caucasian
Americans failed to demonstrate this association [21];
conversely, a haplotype derived from SNPs in introns
3 (rs2448347), 5 (rs2456772), and 7 (rs1871447) of
CDC2 showed a protective effect against AD in APOE
4 allele noncarriers in our population. The concentra-
tion of both activated CDC2 [22] and RPS6KBs [23]
increases in AD brain and their distribution coincide
with the progression of neurofibrillary degeneration.
NON PROLINE-DIRECTED TAU KINASES
PROLINE-DIRECTED TAU KINASES
CAMK2A MARK 1, 2, 3, 4 PRKACB TTBK1
CDC2 CSNK1D MAPKDYRK1ACDK5 GSK3-ß RPS6KB1
p38 
αß
ERK 
1, 2
JNK 
1,2,3
RPS6KB2
MEK 
1, 2
CDK5R1
IB1
Fig. 2. Tau kinases genes analyzed in relation to Alzheimer’s disease (AD) risk in both this study and the literature. In grey boxes, tau kinases
genes associated to AD susceptibility.
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Possible mechanisms that contribute to the associa-
tion between CDC2 and RPS6KBs polymorphisms and
the risk of AD are unknown, as information about the
expression of these proline-directed kinases at the brain
level in subjects with different genotypes is lacking.
The genes of the two major proline-directed kinases
genes involved in the abnormal hyperphosphorylation
of tau in AD, GSK3- and CDK5, have been associated
with AD risk: subjects carrying the functional haplo-
type conformed by the minor allele of GSK3- (−50,
rs344558) and the major allele of GSK3- (−157,
rs6438552), independently [24] or in combination with
at least one copy of the microtubule-associated pro-
tein tau H2 haplotype [5, 25], had an increase risk for
AD. In a Dutch case-control series [26], the CDK5
haplotype composed of 5´UTR (rs2069442), intron 5
(rs2069454), intron 9 (rs891507 and rs2069459) and
3´UTR (rs9278) was significantly associated with AD
in non-carriers of the APOE 4 allele, but these find-
ings were not confirmed in our Spanish population
[6]; however, we observed that a polymorphism in
the 3´UTR region (rs735555) of the gene activator
of CDK5 (CDK5R1) interacted with the major allele
of GSK3- (−50, rs344558) to decrease AD risk [7].
Finally, a haplotype with markers located from 30 kb
upstream of exon 1 to exon 13 in the proline-directed
tau kinase gene DYRK1A showed association with AD
risk in the Japanese population [27], but we did not
replicate this genetic association [8].
In the tau kinases pathway, our present negative
results with the genes of PRKACB, CAMK2A, MARK
(1, 2, 3 and 4), CSNK1D, p38, IB1, MEK1, and ERK1
are probably not due to insufficient statistical power,
because our sample size had enough power (>82%) to
detect and odds ratio of 1.3 at disease allele frequencies
of 0.20. Conversely, our present positive findings sug-
gest that CDC2 and RPS6KB2 are promising candidate
tau phosphorylation-related genes for AD risk.
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